Browse Conditions Browse Medicines

Headlines for Kyprolis


Kyprolis▼ (carfilzomib) - patient safety update

Kyprolis▼, from Amgen

About medicine

The Medicines and Healthcare products Regulatory Agency (MHRA) have advised of a new possible side effect for patients taking Amgen's multiple myeloma treatment carfilzomib, brand name Kyprolis▼.

The Agency advises that following reports of hepatitis B reactivation associated with carfilzomib; screening for hepatitis B before a patient starts treatment is recommended; as well as screening patients already under treatment with unknown hepatitis B virus serology.

This means that patients taking or about to take Kyprolis and who have previously suffered from hepatitis B should be screened for the condition. If a patients hepatitis B status be unknown they too should be screened for the virus.

You can follow developments on Kyprolis by using our Medicines Tracker service which provides users with updates about the medicines they are interested in.

Read Article


Kyprolis▼ (carfilzomib) - patient safety update

Kyprolis▼, from Amgen

About medicine

The Medicines and Healthcare products Regulatory Agency (MHRA) have advised that Amgen's multiple myeloma treatment carfilzomib, brand name Kyprolis▼ has been associated with cases of cardiac arrest, cardiac failure, and myocardial infarction, including in patients without pre-existing cardiac disorders.

The MHRA recommend that patients taking Kyprolis be monitored for signs and symptoms of cardiac disorders before and during exposure to carfilzomib.

The advice for healthcare professionals is:
  • cases of cardiac arrest, cardiac failure, and myocardial infarction, including fatal cases, have been reported in patients receiving anti-cancer therapy with carfilzomib – not all cases occurred in patients with a pre-existing cardiac disorder
  • monitor patients for signs and symptoms of cardiac disorders before and during treatment with carfilzomib
  • stop carfilzomib if severe or life-threatening cardiac events occur; restarting treatment may be considered at a lower dose once the condition is controlled and the patient is functionally stable
  • report any suspected adverse drug reactions (ADR) associated with carfilzomib via the Yellow Card Scheme

You can follow developments with Kyprolis by using our Medicines Tracker service which provides users with updates about the medicines they are interested in.

Read Article


Kyprolis▼ (carfilzomib) - patient safety update

Kyprolis▼, from Amgen

About medicine

Amgen, the manufacturers of multiple myeloma treatment carfilzomib, brand name Kyprolis▼, have updated the side effect information for the medicine.

Cytomegalovirus infection has been added as an uncommon adverse effect.

Cytomegalovirus (CMV) is a common virus that is usually harmless. Sometimes it causes problems in babies if you catch it during pregnancy (congenital CMV).

CMV is similar to the herpes virus that causes cold sores and chickenpox. Once you have the virus, it stays in your body for the rest of your life. Your immune system usually controls the virus and most people don't realise they have it.

CMV doesn't always cause symptoms. Some people get flu-like symptoms the first time they catch CMV, including:
  • a high temperature of 38C or more
  • aching muscles
  • tiredness
  • feeling sick
  • sore throat
  • swollen glands
If you do have symptoms, they normally get better on their own within about 3 weeks.

You can follow developments on Kyprolis by using our Medicines Tracker service which provides users with updates about the medicines they are interested in.

Read Article


NICE approve multiple myeloma treatment, carfilzomib (Kyprolis)

Kyprolis▼, from Amgen

About medicine

14th June 2017. NICE have approved NHS England's use of Amgen's multiple myeloma treatment carfilzomib (Kyprolis). This means the use of the medicine within the conditions set by NICE will be paid for by the NHS and used where doctors think it is suitable.

Read Article


New side effects added to patient information for Kyprolis

Kyprolis▼, from Amgen

About medicine

Amgen's multiple myeloma treatment carfilzomib, Kyprolis, has had the side-effect of tinnitus added to the patient leaflet. For more information see full article.

Read Article


Reporting of suspected adverse reactions

Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.


Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.